Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: The role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system

Paul McGowan; Nicole Nelles; Jana Wimmer; Dawn Williams; Jianguo Wen; Marilyn Li; April A. Ewton; Choladda Curry; Youli Zu; Andrea Sheehan; Chung Che Chang

doi:10.1309/AJCP3FEPX5BEEKGX

Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: The role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system

Paul McGowan, Nicole Nelles, Jana Wimmer, Dawn Williams, Jianguo Wen, Marilyn Li, April A. Ewton, Choladda Curry, Youli Zu, Andrea Sheehan, Chung Che Chang

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

The goal of this study was to evaluate routine flow cytometric (FC) immunophenotypic markers in differentiating between Burkitt lymphoma (BL) and CD10+ diffuse large B-cell lymphoma (DLBCL). We performed retrospective analysis of FC data from 55 patients. We evaluated 9 FC parameters: forward and side scatter (FSC and SSC); mean fluorescent intensity (MFI) for CD20, CD10, CD38, CD79b, CD43, and CD71; and the percentage of neoplastic cells positive for CD71 (%CD71). The FSC; MFIs of CD10, CD43, CD79b, and CD71; and %CD71 cells were significantly different between BL and CD10+ DLBCL (P < .05; Student t test). A 5-point scoring system (FSC, %CD71, and MFIs of CD43, CD79b, and CD71) was devised, and 6 (60%) of 10 BLs scored 3 or greater and 1 (10%) of 10 CD10+ DLBCLs scored 3 (P = .04; χ ²). Our findings indicate that routine FC parameters can aid in differentiating BL from CD10+ DLBCL. Copyright

Original language	English (US)
Pages (from-to)	665-670
Number of pages	6
Journal	American Journal of Clinical Pathology
Volume	137
Issue number	4
DOIs	https://doi.org/10.1309/AJCP3FEPX5BEEKGX
State	Published - Apr 2012

Keywords

Burkitt lymphoma
CD10+ diffuse large B-cell lymphoma
Flow cytometry

ASJC Scopus subject areas

Pathology and Forensic Medicine

Access to Document

10.1309/AJCP3FEPX5BEEKGX

Cite this

McGowan, P., Nelles, N., Wimmer, J., Williams, D., Wen, J., Li, M., Ewton, A. A., Curry, C., Zu, Y., Sheehan, A., & Chang, C. C. (2012). Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: The role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system. American Journal of Clinical Pathology, 137(4), 665-670. https://doi.org/10.1309/AJCP3FEPX5BEEKGX

Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: The role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system. / McGowan, Paul; Nelles, Nicole; Wimmer, Jana et al.
In: American Journal of Clinical Pathology, Vol. 137, No. 4, 04.2012, p. 665-670.

Research output: Contribution to journal › Article › peer-review

McGowan, P, Nelles, N, Wimmer, J, Williams, D, Wen, J, Li, M, Ewton, AA, Curry, C, Zu, Y, Sheehan, A & Chang, CC 2012, 'Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: The role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system', American Journal of Clinical Pathology, vol. 137, no. 4, pp. 665-670. https://doi.org/10.1309/AJCP3FEPX5BEEKGX

@article{babd24230c2c4f5da16d407b270b6dd5,

title = "Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: The role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system",

abstract = "The goal of this study was to evaluate routine flow cytometric (FC) immunophenotypic markers in differentiating between Burkitt lymphoma (BL) and CD10+ diffuse large B-cell lymphoma (DLBCL). We performed retrospective analysis of FC data from 55 patients. We evaluated 9 FC parameters: forward and side scatter (FSC and SSC); mean fluorescent intensity (MFI) for CD20, CD10, CD38, CD79b, CD43, and CD71; and the percentage of neoplastic cells positive for CD71 (\%CD71). The FSC; MFIs of CD10, CD43, CD79b, and CD71; and \%CD71 cells were significantly different between BL and CD10+ DLBCL (P < .05; Student t test). A 5-point scoring system (FSC, \%CD71, and MFIs of CD43, CD79b, and CD71) was devised, and 6 (60\%) of 10 BLs scored 3 or greater and 1 (10\%) of 10 CD10+ DLBCLs scored 3 (P = .04; χ 2). Our findings indicate that routine FC parameters can aid in differentiating BL from CD10+ DLBCL. Copyright",

keywords = "Burkitt lymphoma, CD10+ diffuse large B-cell lymphoma, Flow cytometry",

author = "Paul McGowan and Nicole Nelles and Jana Wimmer and Dawn Williams and Jianguo Wen and Marilyn Li and Ewton, \{April A.\} and Choladda Curry and Youli Zu and Andrea Sheehan and Chang, \{Chung Che\}",

year = "2012",

month = apr,

doi = "10.1309/AJCP3FEPX5BEEKGX",

language = "English (US)",

volume = "137",

pages = "665--670",

journal = "American Journal of Clinical Pathology",

issn = "0002-9173",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma

T2 - The role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system

AU - McGowan, Paul

AU - Nelles, Nicole

AU - Wimmer, Jana

AU - Williams, Dawn

AU - Wen, Jianguo

AU - Li, Marilyn

AU - Ewton, April A.

AU - Curry, Choladda

AU - Zu, Youli

AU - Sheehan, Andrea

AU - Chang, Chung Che

PY - 2012/4

Y1 - 2012/4

N2 - The goal of this study was to evaluate routine flow cytometric (FC) immunophenotypic markers in differentiating between Burkitt lymphoma (BL) and CD10+ diffuse large B-cell lymphoma (DLBCL). We performed retrospective analysis of FC data from 55 patients. We evaluated 9 FC parameters: forward and side scatter (FSC and SSC); mean fluorescent intensity (MFI) for CD20, CD10, CD38, CD79b, CD43, and CD71; and the percentage of neoplastic cells positive for CD71 (%CD71). The FSC; MFIs of CD10, CD43, CD79b, and CD71; and %CD71 cells were significantly different between BL and CD10+ DLBCL (P < .05; Student t test). A 5-point scoring system (FSC, %CD71, and MFIs of CD43, CD79b, and CD71) was devised, and 6 (60%) of 10 BLs scored 3 or greater and 1 (10%) of 10 CD10+ DLBCLs scored 3 (P = .04; χ 2). Our findings indicate that routine FC parameters can aid in differentiating BL from CD10+ DLBCL. Copyright

AB - The goal of this study was to evaluate routine flow cytometric (FC) immunophenotypic markers in differentiating between Burkitt lymphoma (BL) and CD10+ diffuse large B-cell lymphoma (DLBCL). We performed retrospective analysis of FC data from 55 patients. We evaluated 9 FC parameters: forward and side scatter (FSC and SSC); mean fluorescent intensity (MFI) for CD20, CD10, CD38, CD79b, CD43, and CD71; and the percentage of neoplastic cells positive for CD71 (%CD71). The FSC; MFIs of CD10, CD43, CD79b, and CD71; and %CD71 cells were significantly different between BL and CD10+ DLBCL (P < .05; Student t test). A 5-point scoring system (FSC, %CD71, and MFIs of CD43, CD79b, and CD71) was devised, and 6 (60%) of 10 BLs scored 3 or greater and 1 (10%) of 10 CD10+ DLBCLs scored 3 (P = .04; χ 2). Our findings indicate that routine FC parameters can aid in differentiating BL from CD10+ DLBCL. Copyright

KW - Burkitt lymphoma

KW - CD10+ diffuse large B-cell lymphoma

KW - Flow cytometry

UR - https://www.scopus.com/pages/publications/84860595836

UR - https://www.scopus.com/inward/citedby.url?scp=84860595836&partnerID=8YFLogxK

U2 - 10.1309/AJCP3FEPX5BEEKGX

DO - 10.1309/AJCP3FEPX5BEEKGX

M3 - Article

C2 - 22431545

AN - SCOPUS:84860595836

SN - 0002-9173

VL - 137

SP - 665

EP - 670

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

IS - 4

ER -

Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: The role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this